The company reported earnings of 24 cents a share, which beat the consensus estimate of 17 cents from analysts polled by Thomson Reuters. Revenue totaled $17.9 million, which was short of analysts' estimate of $19.4 million.
Enzymotec also issued guidance for the full year 2014 of 64 cents a share to 94 cents a share, while analysts expect 86 cents a share. The company expects full year revenue based on the proportionate consolidation method of $90 million to $110 million, while analysts expect $92.95 million. Based on the equity method, Enzymotec expects revenue of $68 million to $85 million.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
The stock was down 28.13% to $14.54 at 12:32 p.m.